tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Boston Scientific Corp

BSX
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
45.370USD
+0.860+1.93%
์‹œ์žฅ ์šด์˜ ์‹œ๊ฐ„ย 10/22, 13:26๏ผˆET๏ผ‰
67.44B์‹œ๊ฐ€์ด์•ก
18.87P/E TTM

Boston Scientific Corp ์ •๋ณด ํšŒ์‚ฌ

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.

Boston Scientific Corp ํ”„๋กœํ•„

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ BSX
ํšŒ์‚ฌ ์ด๋ฆ„Boston Scientific Corp
์ƒ์žฅ์ผMay 19, 1992
CEOMahoney (Michael F)
์ง์› ์ˆ˜53000
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒMay 19
์ฃผ์†Œ300 Boston Scientific Way
๋„์‹œMARLBOROUGH
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX NASDAQ Basic NYSE
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ01752-1234
์ „ํ™”15086834000
์›น์‚ฌ์ดํŠธhttps://www.bostonscientific.com/en-US/Home.html
์ข…๋ชฉ ์ฝ”๋“œ BSX
์ƒ์žฅ์ผMay 19, 1992
CEOMahoney (Michael F)

Boston Scientific Corp์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Michael F. (Mike) Mahoney
Mr. Michael F. (Mike) Mahoney
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.05M
+9.09%
Mr. John E. Sununu
Mr. John E. Sununu
Independent Director
Independent Director
54.72K
--
Mr. Vance R. Brown
Mr. Vance R. Brown
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
54.24K
--
Mr. Jonathan R. Monson
Mr. Jonathan R. Monson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
39.06K
+2.76%
Ms. Ellen M. Zane
Ms. Ellen M. Zane
Independent Director
Independent Director
27.93K
+13.60%
Mr. David C. Habiger
Mr. David C. Habiger
Independent Director
Independent Director
17.16K
+19.13%
Ms. Emily (Collins) Woodworth
Ms. Emily (Collins) Woodworth
Senior Vice President, Global Finance Controller and Finance Transformation
Senior Vice President, Global Finance Controller and Finance Transformation
2.15K
+21.70%
Mr. Yoshiaki Fujimori
Mr. Yoshiaki Fujimori
Independent Director
Independent Director
2.08K
--
Ms. Catherine R. (Cathy) Smith
Ms. Catherine R. (Cathy) Smith
Independent Director
Independent Director
141.00
--
Mr. Joseph M. (Joe) Fitzgerald
Mr. Joseph M. (Joe) Fitzgerald
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
--
--
๋” ๋ณด๊ธฐ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Michael F. (Mike) Mahoney
Mr. Michael F. (Mike) Mahoney
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.05M
+9.09%
Mr. John E. Sununu
Mr. John E. Sununu
Independent Director
Independent Director
54.72K
--
Mr. Vance R. Brown
Mr. Vance R. Brown
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
54.24K
--
Mr. Jonathan R. Monson
Mr. Jonathan R. Monson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
39.06K
+2.76%
Ms. Ellen M. Zane
Ms. Ellen M. Zane
Independent Director
Independent Director
27.93K
+13.60%
Mr. David C. Habiger
Mr. David C. Habiger
Independent Director
Independent Director
17.16K
+19.13%

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Boston Scientific Corp์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Boston Scientific Corp์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค: Mr. Michael F. (Mike) Mahoney

Boston Scientific Corp(BSX)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2026Q1 ๊ธฐ์ค€์œผ๋กœ, Boston Scientific Corp์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 3113๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 1.40B๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 94.35%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q4 ๋Œ€๋น„ -15512534.00 ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.

Boston Scientific Corp์˜ ์ตœ๋Œ€ ์ˆ˜์ต์›์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
2026Q1 ๊ธฐ์ค€, Boston Scientific Corp์˜ Interventional Cardiology Therapies ๋ถ€๋ฌธ์ด ๊ฐ€์žฅ ๋†’์€ ๋งค์ถœ์„ ๊ธฐ๋กํ–ˆ์œผ๋ฉฐ, ๊ธˆ์•ก์€ 1.33B๋กœ ์ „์ฒด ๋งค์ถœ์˜ 24.49%๋ฅผ ์ฐจ์ง€ํ–ˆ์Šต๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ